Guidelines for the treatment and management of new‐onset diabetes after transplantation1
- 22 April 2005
- journal article
- review article
- Published by Wiley in Clinical Transplantation
- Vol. 19 (3), 291-298
- https://doi.org/10.1111/j.1399-0012.2005.00359.x
Abstract
Although graft and patient survival after solid organ transplantation have improved markedly in recent years, transplant recipients continue to experience an increased prevalence of cardiovascular disease (CVD) compared with the general population. A number of factors are known to impact on the increased risk of CVD in this population, including hypertension, dyslipidemia and diabetes mellitus. Of these factors, new‐onset diabetes after transplantation has been identified as one of the most important, being associated with reduced graft function and patient survival, and increased risk of graft loss. In 2003, International Consensus Guidelines on New‐onset Diabetes after Transplantation were published, which aimed to establish a precise definition and diagnosis of the condition and recommend management strategies to reduce its occurrence and impact. These updated 2004 guidelines, developed in consultation with the International Diabetes Federation (IDF), extend the recommendations of the previous guidelines and encompass new‐onset diabetes after kidney, liver and heart transplantation. It is hoped that adoption of these management approaches pre‐ and post‐transplant will reduce individuals’ risk of developing new‐onset diabetes after transplantation as well as ameliorating the long‐term impact of this serious complication.Keywords
This publication has 29 references indexed in Scilit:
- RESULTS OF LIS2T, A MULTICENTER, RANDOMIZED STUDY COMPARING CYCLOSPORINE MICROEMULSION WITH C2 MONITORING AND TACROLIMUS WITH C0 MONITORING IN DE NOVO LIVER TRANSPLANTATIONTransplantation, 2004
- NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1Transplantation, 2003
- Simvastatin Initiated Early After Heart TransplantationCirculation, 2003
- Management of Dyslipidemia in Adults With DiabetesDiabetes Care, 2003
- Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipientsTransplant International, 2000
- Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipientsTransplant International, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- RACIAL DIFFERENCES IN RENAL TRANSPLANTATION AFTER IMMUNOSUPPRESSION WITH TACROLIMUS VERSUS CYCLOSPORINE1Transplantation, 1998
- GLUCOSE INTOLERANCE AFTER RENAL TRANSPLANTATION DEPENDS UPON PREDNISOLONE DOSE AND RECIPIENT AGE1Transplantation, 1997
- THE LONG-TERM EFFECTS OF THE LIPID-LOWERING AGENT FENOFIBRATE IN HYPERLIPIDEMIC HEART TRANSPLANT RECIPIENTSTransplantation, 1994